Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study

Schober, KE; Rush, JE; Fuentes, VL; Glaus, T; Summerfield, NJ; Wright, K; Lehmkuhl, L; Wess, G; Sayer, MP; Loureiro, J; MacGregor, J; Mohren, N

Abstract

Background The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively. Hypothesis/Objectives To investigate the effects of pimobendan in cats with HCM and recent CHF and to identify possible endpoints for a pivotal study. We hypothesized that pimobendan would be well-tolerated and associated with improved outcome. Animals Eighty-three cats with HCM and recently controlled CHF: 30 with and 53 without left ventricular outflow tract obstruction. Methods Prospective randomized placebo-controlled double-blind multicenter nonpivotal field study. Cats received either pimobendan (0.30 mg/kg q12h, n = 43), placebo (n = 39), or no medication (n = 1) together with furosemide (

Citation

Schober, K., Rush, J., Fuentes, V., Glaus, T., Summerfield, N., Wright, K., …Mohren, N. (2021). Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. Journal of Internal Medicine, 35(2), 789-800. https://doi.org/10.1111/jvim.16054

• Journal Article Type: Article
• Acceptance Date: Jan 20, 2021
• Publication Date: 2021
• Deposit Date: Dec 21, 2021
• Publicly Available Date: Dec 21, 2021
• Print ISSN: 0954-6820
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 35
• Issue: 2
• Pages: 789-800
• DOI: https://doi.org/10.1111/jvim.16054
• Keywords: clinical trial; dynamic outflow tract obstruction; feline; positive inotrope; survival; treatment
• Public URL: https://rvc-repository.worktribe.com/output/1554962